VNRX News and Press, VolitionRX Limited From 11/03/22

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories PR Newswire HENDERSON, Nev. , Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a mul...

VolitionRx ( NYSE: VNRX ) is trading ~10% higher after it signed a global supply agreement with a market leader in pet healthcare for Nu.Q Vet Cancer Test in animals. Volition is also developing cost-effective blood tests to help diagnose and monitor a range o...

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test PR Newswire HENDERSON, Nev. , Oct. 20, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the signing of a globa...

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XB...

NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR...

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...

HENDERSON, Nev., Sept. 12, 2022 (GLOBE NEWSWIRE) -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, today...

Volition Appoints Mickie Henshall as an Independent Director PR Newswire HENDERSON, Nev. , Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX ) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mi...

VolitionRx Limited (VNRX) Q2 2022 Earnings Conference Call August 11, 2022 08:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Ross Osb...

VolitionRX press release ( NYSE: VNRX ): Q2 Cash and cash equivalents as of June 30, 2022, totaled approximately $16.7 million compared with $20.6 million as of December 31, 2021 Continued to manage expenditures carefully with net cash used in operating activities averagin...